Sunshine Biopharma INC

Sunshine Biopharma Inc. announced an adjustment to its Series B Warrants' exercise price, lowering it to $1.2202 due to recent at-the-market stock sales.

Sunshine Biopharma Inc. has entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. to sell up to $4 million in common stock.

Sunshine Biopharma Inc. and its subsidiary Nora Pharma Inc. have entered into a settlement agreement with former Nora President Malek Chamoun, resolving a dispute for CAD$1,500,000.

Sunshine Biopharma CEO Dr. Steve N. Slilaty approved via written consent the issuance of shares and warrant adjustments related to the May 2026 public offering.

Sunshine Biopharma Inc. announced the pricing of a public offering expected to raise approximately $6.0 million before expenses, consisting of units with common stock and warrants.

Sunshine Biopharma Inc. announced its fiscal year 2025 financial results, reporting a 4.1% increase in revenue to $36.3 million and the launch of nine new generic drugs.

Sunshine Biopharma Inc. reported a decrease in revenue for Q2 2026 compared to the prior year, alongside continued net losses, but highlighted progress in its proprietary drug development pipeline and a strengthened cash position.

Sunshine Biopharma Inc. reported an 11.6% increase in Q3 2025 revenue and a 24.0% reduction in net loss, driven by enhanced marketing and improved cost of goods sold.

Sunshine Biopharma Inc. reported a wider net loss in Q2 2025 due to a significant intangible asset impairment and increased operating expenses, despite revenue growth and improved gross profit margins.

Sunshine Biopharma saw an increase in revenue for Q1 2025, but losses continue as the company focuses on generic drug sales and proprietary drug development.

Sunshine Biopharma saw a significant increase in revenue during the third quarter of 2024, but the company still reported a net loss.

Sunshine Biopharma's Q2 2024 results show a significant increase in revenue driven by its generic pharmaceutical segment, despite ongoing losses.

Sunshine Biopharma Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing revenues of $36.3 million and a net loss of $5.98 million.

Sunshine Biopharma's 10-K filing reveals a revenue increase driven by expanded generic drug sales in Canada, but the company still reports a net loss for the year ended December 31, 2024.

Sunshine Biopharma's 2023 revenue significantly increased due to the inclusion of a full year of sales from its subsidiary, Nora Pharma, though the company still reported a net loss.

David Natan, a Director of Sunshine Biopharma Inc., received 58,300 shares of common stock on August 7, 2026.

David Natan, a Director at Sunshine Biopharma Inc., received a stock award of 100,000 shares.

Steve N. Slilaty, CEO of Sunshine Biopharma, reports acquiring and disposing of Series B Preferred Stock on March 4, 2024.

Sunshine Biopharma Inc. announced its 2025 Annual Meeting of Shareholders to vote on director elections, auditor ratification, and an equity incentive plan amendment.

Sunshine Biopharma Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and vote on a significant increase in its equity incentive plan shares.

Sunshine Biopharma Inc. announces its 2024 Annual Meeting of Shareholders to be held virtually on December 10, 2024, to elect directors and ratify the appointment of its independent auditor.

Sunshine Biopharma is implementing a reverse stock split of up to 1-for-60 to regain compliance with Nasdaq's minimum bid price requirement.

Sunshine Biopharma intends to effectuate a reverse stock split of up to 1-for-200 to regain compliance with Nasdaq listing requirements.

Sunshine Biopharma obtained stockholder approval for certain warrant provisions related to a recent $10 million public offering to ensure compliance with Nasdaq listing rules.

Sunshine Biopharma Inc. filed an S-1 registration statement to allow for the cash exercise of 15.5 million Series B Warrants, potentially raising $32 million, while navigating ongoing Nasdaq listing compliance challenges.

Sunshine Biopharma has amended its S-1 filing to update share information for a proposed unit offering.

Sunshine Biopharma is launching a firm commitment, underwritten public offering of units to raise capital for general corporate purposes, including advancing its oncology and antiviral drug pipeline.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed an amended Schedule 13G, reporting beneficial ownership of 9.99% of Sunshine Biopharma Inc. common stock.

Alta Partners LLC has reported beneficial ownership of 200,000 shares, representing 8.6% of the outstanding common stock of Sunshine Biopharma Inc., acquired through warrant exercises.

L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G reporting a 5.83% beneficial ownership stake in Sunshine Biopharma Inc.

Several investment entities and Michael Bigger have reported their beneficial ownership of Sunshine Biopharma Inc. common stock, with a combined stake of 9.47% as of May 18, 2025.

Altium Capital Management LLC and its affiliates have reported a 0% beneficial ownership in Sunshine Biopharma, Inc. common stock, indicating a full divestment of their previous holdings.

Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, and Michael Bigger have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Sunshine Biopharma Inc. common stock.